	1	Jeffrey R. Witham (SBN: 116392) Tanya L. Hunter (SBN: 197761)		
	2	DEWEY BALLANTINE LLP  333 South Grand Avenue		
	-3	Los Angeles, California 90071-1530		
	4	Telephone: (213) 621-6000 Facsimile: (213) 621-6100		
	5	Harvey Kurzweil		
	6	Joseph Angland Aldo A. Badini		
	7	Henry J. Ricardo Paul T. Olszowka		
	8	Brian S. McGrath DEWEY BALLANTINE LLP		
	9	1301 Avenue of the Americas New York, New York 10019-6092		
	10	Telephone: (212) 259-8000 Facsimile: (212) 259-6333		
A. 8	11	Elliot M. Olstein		
E LLI	12	CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI, STEWART		
WEY BALLANTINE L 333 South Grand Avenue angeles, California 90071-	13	& OLSTEIN, P.C. Six Becker Farm Road		
LLAY Gran aliforr	14	Roseland, New Jersey 07068-1739 Telephone: (973) 994-1700		
Y BA South eles, C	15	Facsimile: (973) 994-1744		
DEWEY BALLANTINE LLP 333 South Grand Avenue Los Angeles, California 90071-1530	16	Attorneys for Plaintiff MEDIMMUNE, INC.		
Ľ Ľ	17	TAITED C		
	18			STRICT COURT
	19		)ISTRICT	OF CALIFORNIA
	20	MEDIMMUNE, INC.	\ \{\lambda	Case No. 03-2567 MRP (CTX)
	21	Plaintiff,	{	PLAINTIFF MEDIMMUNE, INC.'S FIRST AMENDED COMPLAINT FOR:
	22	GENENTECH, INC., CITY OF HOPE,	~~d {	Declaratory Judgment;
	23	CELLTECH R&D LTD.	)	2. Patent Invalidity; 3. Patent Unenforceability;
	24	Defendants.	<b>\</b>	4. Non-Infringement; 5. Section 1 of the Sherman Act;
	25		<b>)</b>	6. Section 2 of the Sherman Act; 7. The Cartwright Act; and
	26	L	) )	8. Section 17200 of the Cal. Bus. & Profs. Code.
	27		)	DEMAND FOR JURY TRIAL
	28			
	-			

GNE-GSK 00061405



# DEWEY BALLANTINE LLP 333 South Grand Avenue Los Angeles, California 90071-1530 15

1

2

3

4

5

6

7

8

9

10

11

12

13

14

16

17

18

19

20

21

22 23

24

25

26

27

28

### JURISDICTION AND VENUE

1. Plaintiff MedImmune, Inc. ("MedImmune") seeks declaratory relief pursuant to Fed. R. Civ. P. 57 and 28 U.S.C. §§ 2201 and 2202. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1337 and 1338(a). This Court has jurisdiction over the state law claims asserted hereunder pursuant to 28 U.S.C. § 1367. This Court has personal jurisdiction over defendant Genentech, Inc. ("Genentech") based on its principal place of business in California. This Court has personal jurisdiction over defendant City of Hope ("COH") based on its organization under the laws of the state of California and because its principal place of operation is in California. This Court has personal jurisdiction over defendant Celltech R&D Ltd. ("Celltech") based on its activities in this jurisdiction, including, but not limited to, Celltech's filing of a suit against Genentech under 35 U.S.C. § 146 in the Northern District of California captioned Celltech R&D Ltd. v. Genentech, Inc., Civ. Act 01-3560JCS (N.D. Cal. 2001).

2. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391(b), (c), (d), and 15 U.S.C. §§ 15, 22.

#### THE PARTIES

- 3. Plaintiff MedImmune, by and through its undersigned attorneys, brings this action under antitrust, patent, and unfair competition laws against defendants Genentech, COH and Celltech (collectively, "Defendants") seeking to challenge an illegal and anticompetitive agreement between Genentech and Celltech to secure the issuance of an invalid and unenforceable patent. MedImmune seeks declaratory relief that the patent is invalid, unenforceable and/or not infringed by MedImmune's Synagis® product and that MedImmune owes no payments under license agreements with Genentech.
- MedImmune is a Delaware corporation with its principal place of business 4. in Gaithersburg, Maryland. MedImmune uses biotechnology to develop and produce antibody therapies.
- 5. MedImmune's most successful product, Synagis®, is used for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus

GNE-GSK 00061406



("RSV") in pediatric patients at high risk of RSV disease. RSV infection can be fatal in certain high-risk pediatric patients.

- 6. Defendant Genentech is a Delaware corporation with its principal place of business in South San Francisco, California.
- 7. Defendant COH is a California non-for-profit organization with its principal place of operation in Duarte, California. COH is an assignee of the patent at issue in this case.
- 8. Upon information and belief, Celltech is a British company with its principal place of business in Slough, England. Through an intermediary, the Medical Research Counsel, Celltech sub-licensed MedImmune to use the technology patented in U.S. Patent No. 4,816,397 (the "Boss Patent").

#### **SUMMARY OF THIS ACTION**

- 9. MedImmune has filed this action to challenge an illegal and anticompetitive agreement (the "Agreement") between Genentech and Celltech, two large biotechnology companies, which has the effect of creating a 29-year patent monopoly over what Genentech now claims is the "fundamental technology" required for the artificial synthesis of antibody molecules. MedImmune likewise seeks a declaration that the patent improperly created by this Agreement is invalid, unenforceable and/or not infringed by MedImmune's sale of its antibody product, Synagis®, and that MedImmune owes no payments under license agreements with Genentech.
- 10. Genentech and Celltech have conceded the existence of the Agreement but to date have refused to make it public. Their refusal to disclose the Agreement is purportedly based on confidentiality grounds, notwithstanding the fact that the alleged "invention" at issue is already twenty years old and is described in issued patents. Nonetheless, the parties' own press releases and public filings about the terms of the Agreement have demonstrated its collusive nature and the fact that it benefits only Celltech and Genentech, while harming competition.
- 11. The Agreement between Celltech and Genentech was reached in the context of a dispute that began in the United States Patent and Trademark Office ("PTO")

\_

GNE-GSK 00061407



DEWEY BALLANTINE LLP 333 South Grand Avenue Los Angeles, California 90071-1530 15

1

2

3

4

5

6

7

8

9

10

11

12

13

14

16

17

18

19

20

21

22

23

24

25

26

27

28

between Genentech and Celltech regarding priority of invention. Simply put, Genentech asserted that its assignors had invented the same subject matter claimed by the Boss Patent before Celltech's assignors. Thus, Genentech asserted that the Boss Patent held by Celltech (which had been in effect since 1989) should never have issued and that, instead, a new patent should be granted to Genentech covering this same technology. At the time the Agreement was entered into, the PTO had already rejected Genentech's assertion that it, and not Celltech, was entitled to a patent after conducting an administrative proceeding, known as an interference, that lasted seven years. Additionally, a federal court that considered Genentech's appeal had already rejected Genentech's attempts to obtain summary judgment in its favor.

- 12. Notwithstanding Celltech's legal victories over Genentech in this controversy, some time prior to March 16, 2001 Celltech and Genentech entered into the Agreement, pursuant to which (a) Genentech was declared the winner of the legal dispute between them and awarded priority of invention; (b) the PTO would immediately be asked to revoke Celltech's Boss Patent; and (c) the PTO would be asked to issue simultaneously a new patent to Genentech substantially identical to the Boss Patent (the "New Cabilly Patent"), but with a fresh 17-year life.
- By entering the Agreement, Celltech obtained more benefits than it ever 13. could have achieved simply by prevailing in the lawsuit with Genentech. Significantly, a Celltech Annual Report revealed that Genentech agreed to provide Celltech with a "preferential" license to the New Cabilly Patent. Moreover, although Celltech agreed to an immediate revocation of its Boss Patent, upon information and belief, it suffered no monetary harm from doing so. According to a Celltech press release, Genentech agreed to make Celltech whole for any royalties Celltech would have received had its Boss Patent remained in existence until 2006, when it was to expire. Thus, as part of the Agreement, Genentech agreed to pay Celltech, the nominal "loser" in the legal dispute, the royalties that Celltech would have received had Celltech won. Additionally, Celltech benefits to the extent that Genentech uses the New Cabilly Patent to harm competitors of Celltech.

GNE-GSK 00061408



1

2

3

4 5

6

7

8

9

10

17

18

19

20

21

22

23

24

25

26

27

28

	14.	The Agreement thus provided Genentech with monopoly power based o	n
a brand nev	v patent v	with a full 17-year life that would enable Genentech to deny competitors	
access to w	hat it ass	erts to be fundamental technology necessary for the production of	
monoclona	antibodi	<b>₽</b> ¢	

- 15. The Agreement has profoundly and fundamentally altered the competitive landscape in the biotechnology industry. Before the Agreement, Celltech had granted its competitors broad access to this technology by liberally licensing its Boss Patent. Upon information and belief, in reliance upon the permissive licensing policy of Celltech and the expectation that the patent would expire in 2006, numerous biotechnology companies, including MedImmune, launched research programs to develop monoclonal antibody products that potentially could provide great health benefits to society.
- Many of these health and life-enhancing products are now in clinical trials to obtain FDA approval and are being prepared for commercialization. Genentech's New Cabilly Patent is an obstacle that can prevent these new antibody products from coming to market.
- Genentech is thus in a position to demand a much higher royalty for use of 17. this technology until 2018 (when the New Cabilly Patent will expire). Thus, the Agreement allows Genentech to exclude competitors from the market until 2018 or reap monopoly profits from any licenses which it may choose to grant. Celltech also benefits from this state of affairs because it has "preferential access" to the New Cabilly Patent and to the extent that the New Cabilly Patent may be used to exclude firms that compete with Celltech.
- With its New Cabilly Patent in hand, Genentech immediately exercised its 18. illegally obtained monopoly by advising MedImmune that the New Cabilly Patent covers MedImmune's Synagis® product. As a consequence of this assertion, MedImmune began to make and continues to make significant payments to Genentech under an agreement entered into by MedImmune and Genentech on or about June 5, 1997 (the "1997 License Agreement"). This 1997 License Agreement provided rights to various intellectual property, including the patent application that later matured into the New Cabilly Patent. After issuance of the New Cabilly Patent, MedImmune was forced to obtain additional license agreements from Genentech on or

GNE-GSK 00061409



## DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

